Cetera Investment Advisers’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.86M Buy
62,087
+8,222
+15% +$561K ﹤0.01% 1643
2026
Q1
$3.48M Sell
53,865
-1,495
-3% -$105K ﹤0.01% 1775
2025
Q4
$3.73M Sell
55,360
-4,669
-8% -$314K ﹤0.01% 1678
2025
Q3
$4.4M Buy
60,029
+14,075
+31% +$935K 0.01% 1509
2025
Q2
$2.39M Buy
45,954
+785
+2% +$44.7K ﹤0.01% 1712
2025
Q1
$2.88M Buy
45,169
+3,095
+7% +$180K 0.01% 1474
2024
Q4
$2.01M Buy
42,074
+3,020
+8% +$155K ﹤0.01% 1654
2024
Q3
$2.24M Buy
39,054
+11,368
+41% +$652K ﹤0.01% 1550
2024
Q2
$1.45M Buy
27,686
+8,708
+46% +$382K ﹤0.01% 1807
2024
Q1
$772K Buy
+18,978
New +$711K ﹤0.01% 2271

Other funds holding HALO

Cetera Investment Advisers's HALO Position: Q2 2026 in Review

Cetera Investment Advisers increased its Halozyme (HALO) stake by 15% in Q2 2026, buying an estimated $561K and bringing the position to 62,087 shares worth $4.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1643.

Cetera Investment Advisers first reported a position in HALO in Q1 2024 and has held it in 10 quarters since. 673 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Cetera Investment Advisers held 62,087 shares of Halozyme worth $4.86M as of Q2 2026.
  • Cetera Investment Advisers bought 8,222 Halozyme shares in Q2 2026, an estimated $561K.
  • Halozyme made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #1643 holding.
  • Cetera Investment Advisers first reported a position in Halozyme in Q1 2024 and has held it in 10 quarters since.
  • 673 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.